Ritter Pharmaceuticals Presents Additional Phase 2b Data Showing Adaptation of the Gut Microbiome in Lactose Intolerance Patients at American College of Gastroenterology Scientific Meeting

Los Angeles, California, UNITED STATES

LOS ANGELES, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for lactose intolerance (LI), today presented additional data from its previously completed Phase 2b trial of RP-G28 exhibiting colonic microbiome adaptation and improved lactose tolerance.

“These results are instrumental in understanding the mode of action and effectiveness of RP-G28 in increasing the abundance of gut microbes that are believed to rapidly metabolize lactose, which, in turn, improves lactose tolerance and mitigates the related gastric-based symptoms,” said M. Andrea Azcarate-Peril, Ph.D., Associate Professor of Medicine and Director the Microbiome Core at the University of North Carolina, Chapel Hill. “These results are particularly encouraging as they correlate with similar findings in an 85-subject Phase 2a study of RP-G28, providing us with additional evidence of colonic adaptation with the compound.”

Data from the poster, titled “A Novel Galacto-Oligosaccharide (RP-G28) Promotes Beneficial Adaptations to the Human Gut Microbiome in Patients with Lactose Intolerance,” showed significant increases in several species of bacteria that are associated with lactose metabolism in the active treatment groups, compared to placebo. Notably, bifidobacteria increased in 77.7 percent of patients in the RP-G28 groups (p=<0.001). Further, the poster identified that RP-G28 treatment resulted in improved lactose tolerance and increased milk consumption two times 30 days following treatment, compared to placebo (p=0.014). The data were presented at the Annual Scientific Meeting of the American College of Gastroenterology in Philadelphia, Penn., and the poster will be available on the company’s website:

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc. (www.RitterPharma.com, @RitterPharma) develops novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases. The Company’s lead product candidate, RP-G28, has the potential to become the first FDA-approved treatment for lactose intolerance, a condition that affects millions of people worldwide. RP-G28 is in Phase 3 clinical development with its first Phase 3 study currently underway. The Company is further exploring the therapeutic potential that gut microbiome changes may have on treating/preventing a variety of diseases including: gastrointestinal diseases, cancer, metabolic, and liver disease.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that express the current beliefs and expectations of Ritter Pharmaceuticals’ management. Any statements contained herein that do not describe historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results, performance and achievements to differ materially from those discussed in such forward-looking statements. Factors that could affect our actual results are included in the periodic reports on Form 10-K and Form 10-Q that we file with the Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, except as otherwise required by law, whether as a result of new information, future events or otherwise.


Contact Data